Product Center
Yisuda®Suraxavir Marboxil Tablets
Yisuda®Suraxavir Marboxil Tablets are a novel antiviral medication for the treatment of uncomplicated influenza A and B in previously healthy adolescents aged 12 and above, and adults.
Aurantii® Fructus Immaturus Total Flavonoids Tablet
Aurantii® Fructus Immaturus Total Flavonoids Tablet have good therapeutic effects on common symptoms of functional dyspepsia (such as liver-stomach disharmony, spleen-stomach damp-heat, food stagnation, and spleen-stomach deficiency).
Xiyanping Injection
Xiyanping Injection is a traditional Chinese medicine injection made from total sulfated andrographolide, a key component of Andrographis paniculata. It is part of the National “12th Five-Year Plan” Major Innovative Drug Discovery Project.
Qingruitan®Brivaracetam Tablets
Brivaracetam is an innovative third-generation antiepileptic drug that selectively targets synaptic vesicle protein 2A (SV2A) with high affinity.
Bangkaxin®Esomeprazole Magnesium Enteric-coated Tablets
Bangkaxin® Esomeprazole Magnesium Enteric-coated Tablets are a new generation of proton pump inhibitors (PPIs), approved as a Class 4 chemical drug. It is the only esomeprazole magnesium enteric-coated tablet in China that is bioequivalent to the original brand. It is clinically used for the prevention and treatment of acid-related diseases such as gastroesophageal reflux disease (GERD), peptic ulcers, stress ulcers, Helicobacter pylori eradication, and drug-induced gastric mucosal injury. It is widely used in clinical practice and is a first-line choice for acid suppression therapy and ulcer prevention and treatment.
Zebeining® Palbociclib Capsuless
Zebeining® Palbociclib Capsuless are an oral CDK4/6 inhibitor that selectively targets and inhibits the activity of the CDK4/6-Cyclin D1 complex. This prevents tumor cells from passing through the G1 to S phase checkpoint, blocking the cell cycle and inhibiting tumor cell proliferation.It is primarily used for the treatment of hormone receptor-positive (HR+), HER2-negative locally advanced or metastatic breast cancer, in combination with aromatase inhibitors as initial endocrine therapy for postmenopausal women.
Qingruitan®Brivaracetam Tablets
Brivaracetam is an innovative third-generation antiepileptic drug that selectively targets synaptic vesicle protein 2A (SV2A) with high affinity.
Zebeining® Palbociclib Capsuless
Zebeining® Palbociclib Capsuless are an oral CDK4/6 inhibitor that selectively targets and inhibits the activity of the CDK4/6-Cyclin D1 complex. This prevents tumor cells from passing through the G1 to S phase checkpoint, blocking the cell cycle and inhibiting tumor cell proliferation.It is primarily used for the treatment of hormone receptor-positive (HR+), HER2-negative locally advanced or metastatic breast cancer, in combination with aromatase inhibitors as initial endocrine therapy for postmenopausal women.
Fudingning® Zonisamide Tablets
Zonisamide (ZNS), also known as zonisamide, is a new antiepileptic drug. Since its launch in Japan in 1989, it has been used for over 30 years and has treated more than a million patients worldwide. Due to its unique chemical structure and broad-spectrum, potent antiepileptic effects, it is effective for both focal and generalized epilepsy, as well as epilepsy syndromes.
Xinyang® Abiraterone Acetate Tablets
Xinyang® Abiraterone Acetate Tablets are a highly selective CYP17 enzyme inhibitor that targets multiple sites of androgen biosynthesis throughout the body.
Xinkang® Lacosamide Oral Solution
Xinkang® Lacosamide Oral Solution is another new member of Qingfeng Pharmaceutical's antiepileptic drug family, following the launch of lacosamide tablets and injection.
Xinkang® Lacosamide Injection
Xinkang® Lacosamide Injection is the first third-generation novel antiepileptic injection in China and is the only drug that highly selectively targets the slow-inactivated sodium ion channels.
Xinkang® Lacosamide Tablets
Xinkang® Lacosamide Tablets are the first third-generation novel antiepileptic drug in China, approved for market in January 2019. It is now available in over 58 countries including the U.S., EU, Japan, and China, and has been used by over 500,000 epilepsy patients globally.
Zebeixin® Lenvatinib Mesilate Capsules
Lenvatinib Mesilate Capsules is an oral multi-target kinase inhibitor, primarily targeting VEGFR1-4, FGFR1-3, PDGFRα/β, c-Kit, and RET. It inhibits tumor angiogenesis, suppresses tumor cell growth, and modulates the tumor immune microenvironment. Clinically, it is used to treat unresectable hepatocellular carcinoma (uHCC). The global multi-center REFLECT study showed significant efficacy of Lenvatinib in treating uHCC. It has been included as a first-line treatment for advanced liver cancer in countries such as China, Japan, and the United States.
